The secrets of a successful clinical trial: Compliance, compliance, and compliance

Molecular Interventions

Volumn 11, Issue 2, 2011, Pages 107-110

  Czobor, Pál ^a,b   Skolnick, Phil ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; BICIFADINE; PLACEBO;

CHRONIC PAIN; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; HUMAN; LOW BACK PAIN; META ANALYSIS (TOPIC); NOTE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; VISUAL ANALOG SCALE;

ANIMALS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICATION ADHERENCE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 79955687894     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.11.2.8     Document Type: Note

References (19)

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, and Schacht AL (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214.
2. Miller G (2010) Is Pharma running out of brainy ideas? Science 239:502-504.
3. Becker RE and Grieg NH (2010) Lost in translation: Neuropsychiatric drug development. Sci Transl Med 2:61rv6.
4. Abadie R (2010) The Professional Guinea Pig: Big Pharma and the Risky World of Human Subjects, Duke University Press, Durham. This book provides a disturbing description of the cadre of "professional guinea pigs" who often populate early stage clinical trials. Although the population of interviewees is limited, it is likely the phenomena and abuses described in this book are widespread.
5. (Pubitemid 46681774)
6. Skolnick P (2008) Broad Spectrum Antidepressants: Variations on a monoamine theme. (Ray Fuller Lecture) http://www.aspet.org/multimedia/ video/centennial-meeting-08/.
7. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, and Rosenstock J (2006) RIO-North America Study Group Effect of rimonabant, a cannabinoid- 1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. J Amer Med Assoc 295:761-775. (Pubitemid 43244304)
8. Tizzano J, Stribling DS Perez-Tilve D, Strack A, Frassetto A, Shearman L, Krieter P, Tschöp M, Skolnick P, and Basile AS (2008) The triple uptake inhibitor DOV 21947 reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J Pharmacol Exper Ther 324:1111-1126.
9. Skolnick P, Popik P, Janowsky A, Beer B, and Lippa AS (2003) Antidepressant-like actions of DOV 21, 947: A triple reuptake inhibitor. Eur J Pharmacol 461:99-104. (Pubitemid 36174028)
10. Porsolt RD, and Lenegre A (1992) Behavioral Models of depression, in Experimental Approaches to Anxiety and Depression, (Elliott JM, Heal DJ, and Marsden CA) pp 73-85, John Wiley & Sons, London.
11. Tran P, Skolnick P, Czobor P, Huang N, Bradshaw M, McKinney A, Bymaster F, and Fava M (2010) Efficacy and safety of the novel triple reuptake inhibitor EB-1010 in the treatment of patients with major depressive disorder. Neuropsychopharmacology 35:S320.
12. Basile AS, Janowsky A, Tam E, Benveniste M, Nowak G, Koustova E, Lippa A, and Skolnick P (2007) Characterization of the antinociceptive actions of bicifadine in models of acute, persistent and chronic pain. J Pharmacol Exp Ther 321:1208-1225. (Pubitemid 46762716)
13. Riff D, Huang N, Czobor P, and Stern W (2006) A five-day, multi-center, randomized, placebo-controlled, double-blind, efficacy and safety study of bicifadine and tramadol versus placebo in the treatment of postoperative bunionectomy pain. J Pain 7:S40.
14. Krieter PA, Gohdes M, Musick TJ, Duncanson FP, and Bridson WE (2008) Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab Dispos 36:252-259. (Pubitemid 351185736)
15. Roland MO and Morris RW (1983) A study of the natural history of back pain. Part 1: Development of a reliable and sensitive measure of disability in low back pain. Spine 8:141-144.
16. Baros AM, Latham PK, Moak DH, Voronn K, and Anton RF (2007) What role does measuring compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 31:596-603. Describes the inclusion of riboflavin as a marker to measure compliance in a double-blind, placebo-controlled trial of oral naltrexone in alcoholism. Using a "snapshot of compliance," the effect size of naltrexone was approximately doubled in the compliant population compared to an intentto- treat analysis. (Pubitemid 46434896)
17. Cutler D and Everett W (2010) Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 362:1553- 1555. A "Perspective" describing the public health and economic consequences of medication nonadherence in a general population. The authors discuss the multiple factors that contribute to this phenomenon and offer solutions to increase rates of adherence.
18. Gossec L, Tubach F, Dougados M, and Ravaud P (2007) Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: A systematic literature review. Am J Med Sci 334:248-254. (Pubitemid 351339282)
19. Khan A and Khan S (2003) Placebo in mood disorders: The tail that wags the dog. Curr Opin Psychiat 16:35-39. (Pubitemid 36092330)